SEC Comment Letter for PAVmed Inc. (PAVM) (CIK 0001624326) (PAVM) — Nov 15, 2016
PAVmed Inc. (PAVM) (CIK 0001624326)
Date: Nov. 15, 2016 · CIK: 0001624326 · Accession: 0000000000-16-100958
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214288
Letter
Mail Stop 3030 November 14 , 2016 Via E -Mail Lishan Aklog, M.D. Chief Executive Officer PAVmed Inc. One Grand Central Place, Suite 4600 New York, New York 10165
Re: PAVmed Inc. Registration Statement on Form S-1 Filed October 28, 2016 File No. 333-214288
Dear Dr. Aklog :
We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our com ments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you provide in response to these comments, w e may have additional comments.
Background of this Prospectus, page 2
1. Please tell us whether the securities offered for sale via this registration statement are the securities offered for sale via your registration statement that became effective in Ja nuary 2016. If so, please provide us your analysis of why it is necessary and appropriate for the sale of the securities to be registered on two registration statements.
Item 17. Undertakings, page II -6
2. Please provide all undertakings required by Regulation S -K Item 512, including those required by Item 512(a)(5)(ii) and 512(b) .
Lishan Aklog, M.D. PAVmed Inc. November 14 , 2016 Page 2
We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwiths tanding any review, comments, action or absence of action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration . Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.
Please contact Laurie Abbott at (202) 551 -8071 or me at (202) 551 -3617 with any questions.
Sincerely,
/s/ Russell Mancuso
Show Raw Text
Mail Stop 3030 November 14 , 2016 Via E -Mail Lishan Aklog, M.D. Chief Executive Officer PAVmed Inc. One Grand Central Place, Suite 4600 New York, New York 10165 Re: PAVmed Inc. Registration Statement on Form S-1 Filed October 28, 2016 File No. 333-214288 Dear Dr. Aklog : We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our com ments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, w e may have additional comments. Background of this Prospectus, page 2 1. Please tell us whether the securities offered for sale via this registration statement are the securities offered for sale via your registration statement that became effective in Ja nuary 2016. If so, please provide us your analysis of why it is necessary and appropriate for the sale of the securities to be registered on two registration statements. Item 17. Undertakings, page II -6 2. Please provide all undertakings required by Regulation S -K Item 512, including those required by Item 512(a)(5)(ii) and 512(b) . Lishan Aklog, M.D. PAVmed Inc. November 14 , 2016 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwiths tanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration . Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Laurie Abbott at (202) 551 -8071 or me at (202) 551 -3617 with any questions. Sincerely, /s/ Russell Mancuso Russell Mancuso Bran ch Chief Office of Electronics and Machinery cc: Jeffery M. Gallant, Esq. Graubard Miller